LAS VEGAS, June 10, 2021 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a company focused on developing treatments for
conditions that cause severe pain and drugs with non-addictive,
pain-relieving properties, today announced that it has engaged the
services of DC Consulting LLC, a strategy and management consulting
firm specializing in government affairs, regulatory guidance,
marketing strategy, and public relations services relating to
healthcare, pharmaceuticals, drug policy and prevention, law
enforcement, and building healthy communities.
DC Consulting was founded by former public officials
James W. Carroll, Jr. and
Uttam Dhillon. Mr. Carroll most
recently served as the Director of the Office of National Drug
Control Policy, a position he held since 2018. Earlier, he
served as the White House Deputy Chief of Staff, General
Counsel in the Office of Management and Budget, and as Deputy
White House Counsel. Mr. Dhillon recently served as Director of
INTERPOL Washington. He previously served as the Acting
Administrator of the Drug Enforcement Administration and
as Deputy White House Counsel. Earlier, he held senior posts at the
Department of Homeland Security and the Department of Justice.
"The consulting services of DC Consulting LLC, led by renowned
former national drug enforcement officials, will be a tremendous
asset in our mission to reduce the need for opioid prescriptions
for conditions that cause pain," said Tony Isaac, President and Chief Executive
Officer of JanOne. "JAN101, our sustained release sodium nitrite
tablet, has demonstrated positive data in Phase 2a clinical trials,
with Phase 2b trials expected to
begin in the near future for the treatment of peripheral artery
disease (PAD). Other potential indications for JAN101 include
diabetic neuropathy, wound healing, and vascular inflammation. By
alleviating disease-associated pain at the source, JAN101 may be an
impactful solution in the war on prescription opioid abuse."
Mr. Carroll said, "JanOne aims to be a leader in effective and
safe pain management by always putting the needs of patients as a
top priority."
Mr. Dhillon added, "We are excited to be working with the
innovative team at JanOne. Reducing the need for prescription
opioids is a critical step in combatting the opioid epidemic."
Under terms of the engagement, DC Consulting will assist JanOne
in establishing and maintaining key contacts with relevant federal
and state governmental entities and public and private
organizations. The firm will also advise JanOne on relevant federal
legislation and make strategic recommendations consistent with the
Company's business objectives.
About JanOne
JanOne (NASDAQ: JAN) is focused on developing treatments for
diseases that cause severe pain. By alleviating pain at the source,
JanOne aims to reduce the need for opioid prescriptions to treat
disease associated pain that can lead to opioid abuse. The company
is also exploring solutions for non-addictive pain medications. Its
lead candidate JAN101 is for treating peripheral artery disease
("PAD"), a condition that affects over 8.5 million Americans.
JAN101 demonstrated positive results in a Phase 2a clinical trial,
and Phase 2b trials are expected to begin in the near
future. JanOne is dedicated to funding resources toward innovation,
technology, and education for PAD, associated vascular conditions
and neuropathic pain. For more information,
visit www.janone.com.
Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. In accordance with the safe harbor provisions of this Act,
statements contained herein that look forward in time that include
everything other than historical information, including statements
relating to the commencement of Phase 2b trials, whether there are other indications
for JAN101, and whether JAN101 may be an impactful solution in the
war on prescription opioid abuse. These forward-looking statements
can be identified by terminology such as "will," "aims," "may,"
"expects," "expected," "potential," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
JanOne may also make written or oral forward-looking statements in
its periodic reports to the U.S. Securities and Exchange Commission
(the "SEC") on Forms 10-K and 10-Q, Current Reports on Form 8-K, in
its annual report to stockholders, in press releases, and other
written materials and in oral statements made by its officers,
directors or employees to third parties. There can be no assurance
that such statements will prove to be accurate and there are a
number of important factors that could cause actual results to
differ materially from those expressed in any forward-looking
statements made by the company, including, but not limited to,
plans and objectives of management for future operations or
products, the market acceptance or future success of our products,
and our future financial performance. The company cautions that
these forward-looking statements are further qualified by other
factors including, but not limited to, those set forth in the
company's Annual Report on Form 10-K for the fiscal year
ended January 2, 2021 and other SEC filings (available
at http://www.sec.gov). JanOne undertakes no obligation to
publicly update or revise any statements in this release, whether
as a result of new information, future events, or otherwise.
Investor Relations & Media
Contact
IR@Janone.com
1 (800) 400-2247
View original content to download
multimedia:http://www.prnewswire.com/news-releases/janone-engages-dc-consulting-llc-for-government-and-private-sector-initiatives-301309987.html
SOURCE JanOne Inc.